



Taddle Creek

MEDICAL DIRECTIVE

Family Health Team

Title:	Administration and Interpretation of Mantoux Tuberculin Test	Number:	TCFHT-MD14
Activation Date:	09-Sep-2014	Review Date:	11-May-2020
Next Review Date:	11-May-2021		

Sponsoring/Contact Person(s)
(name, position, contact particulars):

Victoria Charko, RN
790 Bay Street, Suite 522, Box 58/59
Toronto, Ontario M5G 1N8
Tel: 416-591-1222

Jessica Yu, MD
790 Bay Street, Suite 522, Box 58/59
Toronto, Ontario M5G 1N8
Tel: 416-591-1222

Order and/or Delegated Procedure:	Appendix Attached: <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes Title:
The implementers may administer and interpret the results of a Mantoux Tuberculin Skin Test (TST) in accordance with the conditions identified in this directive.	
Recipient Patients:	Appendix Attached: <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes Title: Appendix A – Authorizer Approval Form
Recipients must: <ul style="list-style-type: none">• Be active patients of a TCFHT primary care provider who has approved this directive by signing the Authorizer Approval Form• Meet the conditions identified in this directive	
Authorized Implementers:	Appendix Attached: <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes Title: Appendix B – Implementer Approval Form
Implementers must be TCFHT-employed Regulated Health Care Providers or Physician Assistant (under the supervision of a physician).	
Implementers must complete the following preparation and sign the Implementer Approval Form: <ul style="list-style-type: none">• Certification in CPR (minimum level C plus AED training)	

- Demonstrate clinical competence and knowledge to supervising physician(s) and/or nurse practitioner and administer at least 3 TSTs under his/her supervision
- Review and be familiar with Table 1 (pg.18), Clinical Picture of Pulmonary TB (pgs. 44-45) and Chapter 4 (pgs. 63-80) in the *Canadian Tuberculosis Standards 7th Edition*, accessible from: https://strauss.ca/OEMAC/wp-content/uploads/2013/11/Canadian_TB_Standards_7th-edition_English.pdf
- Review and be familiar with *Tuberculosis: Information for Health Care Providers – 5th Edition* by The Lung Association, accessible from: <https://www.rcdhu.com/wp-content/uploads/2018/12/TB-Information-for-Health-Care-Providers-5th-edition.pdf>
- Review and be familiar with the most current Tubersol[®] product monograph, accessible from: <http://products.sanofi.ca/en/tubersol.pdf>
- Review most current guidelines for anaphylaxis management as per “Anaphylaxis” in the *Canadian Immunization Guide: Part 2 – Vaccine Safety: Early vaccine reactions including anaphylaxis*, accessible from: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-2-vaccine-safety/page-4-early-vaccine-reactions-including-anaphylaxis.html>

Indications:

Appendix Attached: No Yes
 Title:

The implementers are authorized to administer and interpret TSTs to assist in diagnosing or excluding latent TB infection in any patients who:

- Are close contacts of persons with active pulmonary tuberculosis (TB);
- Were born in or are visitors from TB-endemic countries, especially those < 20 years old and immigrants who have arrived in the last two years;
- Are travellers to countries with high TB incidence;
- Are from Aboriginal communities with high incidence of TB;
- Are homeless/underhoused;
- Are injection drug users;
- Reside or work in communal care settings (e.g. shelters, correctional facilities, long-term care centres);
- Are at increased risk of progression to active TB disease due to impaired immunity (e.g. HIV/AIDS, transplant, head/neck cancer, chronic renal failure requiring hemodialysis);
- Have radiographic evidence of old, healed TB without history of treatment

The implementer will consult with a physician or nurse practitioner if any contraindication to receiving the test is identified in the initial screening. After consultation, if the TST is to be administered, the physician or nurse practitioner will review the documentation recorded by the implementer in the EMR and will document his/her assessment as well.

Contraindications:

- Known active TB or well-documented history of treatment for TB infection/disease in past
- Documented positive TST
- A previous severe reaction to TST (e.g. blistering)
- Extensive burns or eczema at the TST site
- History of an anaphylactic reaction to a previous TST or to any components of the Tuberculin Purified Protein Derivative (PPD) (e.g. Tubersol)

When to defer TST:

- Patient currently has a major viral infection (e.g. measles, mumps, rubella, varicella, yellow fever) – defer for 4 weeks after infection
- Patient was immunized with live virus vaccine(s) in the past month* (e.g. measles, mumps, rubella, varicella, yellow fever) – defer by 30 days from date of immunization

When NOT to defer:

- Recent immunization with non-live-virus vaccines or immunization with any vaccine on the same day*
- Previous BCG vaccination
- Pregnancy or breastfeeding
- Common cold
- Use of low-dose systemic corticosteroids (i.e. a steroid dose equivalent to < 15mg prednisone daily)
- History of a non-documented, non-blistering positive TST reaction

*Note: A TST may be administered before or even on the same day as live-virus immunizations but at a different site.

Consent:

Appendix Attached: No Yes
Title:

The implementer will obtain verbal consent from the patient or legal substitute decision maker and will explain any potential risks and benefits prior to administering the TST.

Guidelines for Implementing the Order/Procedure:

Appendix Attached: No Yes
Title:

Authorized implementer may administer or interpret the TST result upon receiving consent and after confirming appropriateness (according to Canadian Tuberculosis Standards 7th Edition). Universal precautions will be taken to minimize transmission of bloodborne pathogens and ensure patient and clinician safety. If the reaction to the TST is positive, the implementer will evaluate possible risk factors for active TB and will notify a physician or nurse practitioner of the positive TST result for management.

A physician or nurse practitioner must be present in the clinic in case he/she is needed for assessment and decision-making for patients who have contraindications to receiving the test, present with a positive TST result or to provide emergency treatment should a patient experience an acute reaction to the PPD.

Documentation and Communication:

Appendix Attached: No Yes
Title: Appendix C – TCFHT-MD14 Stamp

Implementer will document administration of the test in a chart note in the patient's EMR file using the stamp TCFHT-MD14_Mantoux_Tuberculin_Test (see Appendix C). Information to be documented will include: brand and dose of PPD used, lot #, expiry date, area of body that is injected and details of any adverse reaction that occurs. A physician or nurse practitioner will be alerted immediately if an adverse reaction occurs.

The implementer will advise the patient of the schedule for the reading of the TST result and, if applicable, when to return for the subsequent TST.

Review and Quality Monitoring Guidelines:

Appendix Attached: No Yes
Title:

- Review will occur annually on the anniversary of the activation date. Review will involve a collaboration between the authorizing primary care providers and the approved implementers.
- If new information becomes available between routine reviews, such as the publishing of new clinical practice guidelines, and particularly if this new information has implications for unexpected outcomes, the directive will be reviewed by an authorizing primary care provider and a minimum of one implementer.
- At any such time that issues related to the use of this directive are identified, TCFHT must act upon the concerns and immediately undertake a review of the directive by the authorizing primary care providers and the authorized implementers.
- This medical directive can be placed on hold if routine review processes are not completed or if indicated for an ad hoc review. During the hold, implementers cannot perform the procedures under authority of the directive and must obtain direct, patient-specific orders for the procedure until it is renewed.

References:

Assessment and Treatment of Latent Tuberculosis Infection, accessible from:

<https://www.toronto.ca/wp-content/uploads/2017/10/8e93-tph-TB-LTBI-4pager-TPH-Guideline-2013.pdf>

Canadian Immunization Guide: Part 2 – Vaccine Safety: Early vaccine reactions including anaphylaxis, accessible from: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-2-vaccine-safety/page-4-early-vaccine-reactions-including-anaphylaxis.html>

Canadian Tuberculosis Standards 7th Edition, accessible from: https://strauss.ca/OEMAC/wp-content/uploads/2013/11/Canadian_TB_Standards_7th-edition_English.pdf

Tuberculosis: Information for Health Care Providers – 5th Edition, accessible from:

<https://www.rcdhu.com/wp-content/uploads/2018/12/TB-Information-for-Health-Care-Providers-5th-edition.pdf>

Tubersol[®] product monograph, accessible from: <http://products.sanofi.ca/en/tubersol.pdf>

Appendix A:

Authorizer Approval Form

Name	Signature	Date
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>
<hr/>	<hr/>	<hr/>

Appendix B:

Implementer Approval Form

To be signed when the implementer has completed the required preparation, and feel they have the knowledge, skill, and judgement to competently carry out the actions outlined in this directive.

Name

Signature

Date

_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

Appendix C:**TCFHT-MD14 Stamp**

S: Requires «annual»«2-step»«2nd step» Mantoux Tuberculin Test (TST) for
«school»«work»«volunteering»«•»

«- First test done • week«s» ago - negative result»

«- No hx of previous TSTs»«- Hx of previous TSTs - «negative»«positive»«non-documented positive»
result, no adverse reaction»

- No hx of known active TB or treatment for TB

- «No» recent or current major viral illness, «no» live virus vaccinations in past month «- •»

O/E:

- «L»«R» forearm skin clear

- Tubersol administered at •:•«am»«pm»

0.1ml intradermal • forearm

Lot #: •, Exp: •

A:

- Successful TST, adequate bleb achieved

- No adverse reaction

P:

- Advised pt to wait X 15 mins post-injection for observation; no adverse reaction reported

- Pt to RTC in 48-72hrs for interpretation of TST result

«- Pt aware to RTC in 1-3 weeks for 2nd step TST»

*actions and interventions in accordance with Medical Directive TCFHT-MD14

Appendix D:

Assessment and Treatment of Latent Tuberculosis Infection

Quick
referenceAssessment and Treatment
Of Latent Tuberculosis Infection

Indications for tuberculin skin testing (TST)

- To diagnose tuberculosis TB infection in persons at increased risk for progression to active disease
- It is **not** reliable for diagnosis of active disease

Who should be tested

- Contacts of persons recently diagnosed with active pulmonary TB
- Foreign-born persons and visitors from TB-endemic countries, especially those <20 years old and those who have arrived in the last two years
- All refugees, between the ages of 20 and 50, from countries with a high incidence of TB, as soon as possible, after their arrival in Canada¹
- All other adult immigrants if they have risk factors that increase the risk of active tuberculosis¹
- People who are at increased risk of progression to active TB disease
- People with radiographic evidence of old, healed TB and no history of treatment
- Health care workers at risk for occupational exposure to TB
- Staff and residents in communal care, including correctional facilities, long-term care, and shelters/services for homeless/underhoused
- Persons from Aboriginal communities with high rates of TB
- Travelers to countries with high TB incidence²

Tuberculin testing is generally discouraged for those with no elevated risk of infection with TB and no known risk factors for progression to active TB disease.

Risk factors for development of active tuberculosis in those with latent TB infection (LTBI)

High risk – screen at any age

- Acquired immunodeficiency syndrome (AIDS)
- Human immunodeficiency virus infection (HIV)
- Transplantation (related to immune-suppressant therapy)
- Silicosis
- Chronic renal failure requiring hemodialysis
- Carcinoma of head/neck
- Recent TB infection (≤2 years)
- Abnormal chest x-ray (fibronodular disease)

Moderate risk/increased risk-screen ≤ 65 years

- Treatment with TNF inhibitors
- Diabetes mellitus
- Treatment with glucocorticoids equivalent to prednisone (≥15mg/day)
- Young age when infected (0–4 years)
- Heavy alcohol consumption (≥3 drinks/day)
- Underweight (≤90% ideal body weight, generally BMI ≤20)
- Cigarette smoking (1 pack/day)
- Abnormal chest x-ray (granuloma)

Low risk ≤ 50 years

- Person with positive TST, no known risk factors, normal chest x-ray ("low risk reactor")

Contraindications for tuberculin skin testing

- Documented positive skin test** or **active tuberculosis** in the past
- Tuberculin reactions that have severely blistered in the past
- Clear past history of treatment for TB infection or disease
- Extensive burns or eczema at the usual test site. Choose another site
- Major viral infections or live-virus vaccinations in the past month, for example, measles, mumps, rubella, varicella or yellow fever

The following are **not** contraindications for TB skin testing:

- Common cold
- Immunized with any vaccine on the same day
- Recently been vaccinated with non-live virus vaccines
- Pregnant or breastfeeding
- Received BCG vaccination in the past
- History of positive tuberculin skin test that is **not** documented
- Taking low dose corticosteroids (≤15 mg Prednisone daily)

Technique for the skin test

- 0.1ml (5-TU) of purified protein derivative (PPD)
- Inject **intradermally** on volar (inner) aspect of the forearm
- Injection should raise a small wheal approximately 6-10 mm in diameter, which will disappear in 10–15 minutes

Reading

- Skin test must be read by a trained health professional. Self reading is inaccurate and should not be done.
- Read 48–72 hours after administration.
- Use a ruler or caliper to measure **induration** of the transverse diameter (i.e., at right angle to the long axis of the forearm). Record in millimetres (mm) even if no induration (0 mm).
- Do not measure erythema (redness).

Interpretation

Proper interpretation of the TST should include all of the following:

- Size of the reaction (induration), in mm
- Predictive value of the test (considering likelihood of true exposure, false-negative and/or false-positive reactions)
- Risk of progression to active disease

Online TST interpreter available at the McGill University website: www.tstin3d.com

TST Result	Situation in which reaction is considered positive
0–4 mm	In general this is considered negative, and no treatment is indicated. Children under 5 years of age who are contacts of an infectious case should be treated pending results of repeat TST 8 weeks after exposure.
≥5 mm	<ul style="list-style-type: none"> HIV Infection Close contact of active contagious case within past 2 years Abnormal chest x-ray with fibronodular disease Treatment with immunosuppressive medications (e.g., TNF inhibitors) End-stage Renal Disease/Dialysis
≥10 mm	All others, including diabetes, malnutrition (<90% ideal body weight), cigarette smoking, daily alcohol consumption (>3 drinks/day), silicosis, hematologic malignancies (leukemia, lymphoma) and certain carcinomas (e.g., head and neck)

Adapted from Canadian TB Standards (CTS), 2013, p. 46A, Table 2

Causes of false-negative TST

- Error in administration or reading
- Age <6 months or advanced age
- Immunization within the past 4 weeks with MMR, varicella or yellow fever
- Immune suppression
- Major viral illness in the past 4 weeks (e.g., measles, mumps, mononucleosis)
- Severe malnutrition, chronic renal failure, severe physiological stress (surgery, burns)
- Active tuberculosis** or other severe illness

Causes of false-positive TST

- Infection with non-tuberculous mycobacteria (i.e., environmental mycobacteria)
- Prior BCG vaccination (see below for details)

BCG

May have been received by population groups including:

- Persons born in developing countries or TB-endemic countries and many European countries
- Aboriginal persons from communities with high rates of TB
- Persons born in Canada prior to 1970's, particularly health-care workers (detailed information available on PHAC website)

BCG vaccination and relationship to TST results

Received in infancy	Unlikely to cause a tuberculin reaction of 10 mm or greater after 10 years of age or older.
Received at 1 to 5 years of age	10–15% will have a positive TST up to 25 years later.
Received at 6 years or older	40% chance of having persistent positive TST later in life.

Source: CTS, 2013, p. 27A

Ignore prior history of BCG vaccination for:

- Close contacts of an active case
- Populations with a high risk of developing infection
- Immigrants from countries with a high burden of TB – BCG World Atlas available online at: www.bcgatlas.org
- Persons from Aboriginal communities with high rates of TB
- BCG vaccination in infancy and person tested is now age 10 years or older
- Immunocompromised, including HIV and renal failure
- Diabetes
- Chest x-ray consistent with old healed inactive TB

Two-step TST

- Should be performed **only** for people who will be getting serial TSTs at regular intervals (e.g., health care workers and correctional service workers)
- Distinguishes a booster effect (due to previous infection) from a conversion due to recent infection
- Consider for travelers to high-prevalence countries for prolonged visits
- If the first test is negative, do a second skin test 1 week to 4 weeks later

Management for positive TST

- All persons with a positive TST should be reported to your local public health department.
- Persons with a positive TST should be further evaluated to rule out active TB disease.

This evaluation should include the following: Clinical picture, interpretation of radiographic findings and sputum collection, if necessary.

Evaluation

1. Clinical picture (history, risk factors, and physical examination for signs and symptoms of active TB disease).
2. Chest x-ray, anteroposterior (AP) and lateral views.
3. In the presence of symptoms or chest x-ray findings consistent with pulmonary TB, collect 3 sputum specimens to send for AFB Smear and Culture. The sputum specimens (either spontaneous or induced) can be collected on the same day, at least 1 hour apart.

1. Clinical picture

- Many patients with pulmonary tuberculosis have a normal physical exam, even if symptomatic.
- The most common symptom of pulmonary TB disease is a new or worsening cough of at least 2–3 weeks duration.
- Cough is initially dry and may become productive after several weeks.
- Fever and night sweats may be absent in the very young and elderly.
- Hemoptysis, anorexia, weight loss and chest pain are generally seen in more advanced disease.

Note: TB can occur in any part of the body with site-specific symptoms. Lymph node TB is the most common extra-pulmonary site.

2. Interpretation of radiographic findings

- Chest x-rays should always be interpreted in the context of clinical and laboratory findings.
- The interpretation of chest x-rays is highly variable between readers.
- 10% of persons with HIV infection and active TB disease will have a normal chest x-ray.

Source: CTS, 2013, p. 17A

3. Sputum collection and timelines for results

Sputum collection

- Collect 3 sputum specimens (either spontaneous or induced). The specimens can be collected on the same day, at least 1 hour apart (early morning collection not essential).
- Collect 5 to 10 cc of sputum per specimen.
- If immediate delivery (<1 hour) is not possible, protect specimens from light in a paper bag and refrigerate at 4°C pending transport to the lab. Deliver to the lab as soon as possible to avoid overgrowth of normal flora.

Note: Instructions for patient sputum collection can be obtained from your local health department.

Public health lab timelines and results

- Smear for Acid Fast Bacilli (AFB) – results are available in 1 business day from arrival at the lab.
- Amplified Mycobacterium Tuberculosis Direct (AMTD) distinguishes between TB and other non-tuberculous mycobacteria, for example, Mycobacterium Avium Complex (MAC). AMTD is performed automatically on AFB smear positive specimens from new patients – results are available in 2–3 business days from arrival at the lab.
- Culture for Mycobacterium Tuberculosis – results may be available anywhere from 4 days to 7 weeks.
- Sensitivity testing for susceptibility to first-line antituberculosis drugs (4 to 7 days after organism has grown in culture), is done automatically on all positive cultures – first-line results are available in 8–10 business days. Full panel second-line drug sensitivity testing is automatically done if resistance is detected to Rifampin or 2 or more drugs – results are available in 4–15 business days.
- Contact the public health lab in your area for any questions related to tests, timelines and results.

Contacts who are HIV+ or are <age 5 or are <age 18 with a positive TST

- Contacts who are < 5 years of age or are HIV+ should be assessed by a specialist. Window prophylaxis is strongly recommended pending the TST at 8–10 weeks post-exposure.
- Treatment for LTBI should be initiated as soon as active disease is ruled out.
- Children do not require baseline liver function tests unless they have known or suspected liver disease and are taking hepatotoxic drugs.
- Parents and older children should be educated about symptoms indicative of adverse reactions and signs of hepatotoxicity.
- Consider Directly-Observed Prophylactic Therapy (DOPT) by the local public health department, if available.

Refer to Paediatric Latent Tuberculosis Infection (LTBI) Treatment Guidelines at http://www.toronto.ca/health/professionals/communicable_diseases/tb/pdf/paediatric_treatment_ltbi.pdf
Source: CTS, 2013, chpt. 9, 10, 12.

**Quick
reference**

Treatment of latent tuberculosis infection (LTBI)

Approximately **10%** of persons infected with TB will go on to develop active TB disease: **5%** within 2 years of infection and **5%** for the remainder of life.

Treatment of LTBI reduces an individual's risk of developing active TB. Before starting treatment for LTBI, rule out active TB first!

Decision to start latent TB infection (LTBI) treatment – should be based on:

1. Interpretation of TST in context of patient's history:
 - Size of the reaction (induration), in mm
 - Predictive value of the test (considering likelihood of true exposure, false-negative, false-positive reactions)
 - Risk of progression to active disease
 - *Refer to online TST interpreter – <http://www.tstin3d.com>
2. Medical Contraindications (see table below). Patients under 65 years old with no comorbidities have low rates of hepatotoxicity
3. Likelihood of adherence to full length of LTBI treatment
 - Patient ability and commitment
 - Provider ability to continue monthly follow-up for adherence, side effects, etc.
4. Discussion of risks/benefits with patient
5. Active TB has been ruled out (history, risk factors, and physical examination; negative sputum cultures if patient is symptomatic, has abnormal CXR or is being treated with Rifampin).

Source: CTS, 2013, chpt. 4, 6.

Recommendations for treatment of LTBI

Medications are free when ordered through your local public health department

First-Line Regimen	Interval & duration	Oral dosage	Criteria for completion	Comments	Effectiveness
Isoniazid (INH)	Daily for 9 months	Adult: 5 mg/kg/day to a maximum of 300 mg/day	9 months is equivalent to 270 doses. Completing 270 doses within a 12 month period can be considered adequate treatment	<ul style="list-style-type: none"> • Recommended treatment regimen • Provides optimal protection in preventing progression toward active disease • For children, especially those < 5 years old, consult a specialist 	Assuming good adherence to treatment: <ul style="list-style-type: none"> • INH, when taken for 9 months, is up to 90% effective in preventing progression to active disease and is the recommended duration of treatment.
Vitamin B6 (Pyridoxine)	Daily with INH	25 mg		Protects against neurotoxic effects of INH; Usually prescribed, particularly important for clients with diabetes, renal failure, malnutrition, substance abuse or seizure disorders, or for women who are pregnant or breastfeeding.	
2nd-Line/ Alternative Regimen	Interval & duration	Oral dosage	Criteria for completion	Comments	Effectiveness
Isoniazid and Rifampin (INH/RMP)	Daily for 3- 4 months	Adult: <ul style="list-style-type: none"> • INH – 5 mg/kg/ day to a maximum of 300 mg/day • RMP – 10 mg/kg/day to a maximum of 600 mg/day 	For the preferred 4 month regimen, a minimum of 120 doses completed within 6 months can be considered adequate treatment.	Use this regimen in consultation with a specialist. *Consider collecting sputum and pending for culture results prior to initiation to avoid inducing drug resistance. Alternate regimen for persons: <ul style="list-style-type: none"> • Who are unlikely to be able to complete 9 months of INH (i.e., adherence concerns) 	Published efficacy of 3 months of INH/RMP is 64%; 4 months is expected to have higher efficacy. Efficacy and safety is similar to 6-9 months of INH.
Rifampin (RMP)	Daily for 4 months	Adult: 10 mg/kg/day to a maximum of 600 mg/day	A minimum of 120 doses completed within 6 months can be considered adequate treatment.	Use this regimen in consultation with a specialist. *Consider collecting sputum and pending for culture results prior to initiation to avoid inducing drug resistance. Alternate regimen for persons: <ul style="list-style-type: none"> • Who cannot tolerate INH • Who are contacts of INH-resistant TB • Higher risk of side effects if not taken consistently Risk of side effects is higher if Rifampin is not taken consistently. 	Published efficacy rates 63% equivalent to 6 months INH. Excellent safety and high completion rates.

Consultation or referral to a TB specialist is recommended for persons who are:															
<ul style="list-style-type: none"> • HIV positive • Children • Have an abnormal CXR (other than simple granulomas) 		<ul style="list-style-type: none"> • Contacts of multidrug-resistant TB • Pregnant women at high risk of TB 													
Drug	Adverse reactions	Monitoring	Comments												
Isoniazid (INH)	<ul style="list-style-type: none"> • Liver enzyme elevation • Hepatitis • Peripheral neuropathy • CNS • Gastrointestinal • Hematological • Hypersensitivity <p>* Drug interactions – refer to Compendium of Pharmaceuticals and Specialties</p>	<ul style="list-style-type: none"> • Baseline serum aminotransferases • Monitor monthly • Monthly ALT, AST for patients with: <ul style="list-style-type: none"> ▫ Pre-existing liver disease (particularly Hepatitis C) ▫ Age ≥35 ▫ History of alcohol abuse or prior drug induced hepatitis ▫ Pregnant or within 3 months postpartum • If AST level >5 times baseline level, or if symptoms of hepatotoxicity develop (i.e., anorexia, nausea, vomiting, abdominal discomfort, dark-coloured urine, jaundice or scleral icterus), then INH should be stopped and a TB specialist consulted • Repeat monitoring of liver enzymes for patients with symptoms consistent with hepatic side effects 	<p>Hepatitis risk correlated with age:</p> <table border="1"> <thead> <tr> <th>Age Group</th> <th>Risk</th> </tr> </thead> <tbody> <tr> <td>< 20</td> <td>0.1–0.2%</td> </tr> <tr> <td>20–34</td> <td>0.3%</td> </tr> <tr> <td>35–49</td> <td>0.5%</td> </tr> <tr> <td>50–64</td> <td>1.0–3.0%</td> </tr> <tr> <td>≥ 65</td> <td>2.0–5.0%</td> </tr> </tbody> </table> <ul style="list-style-type: none"> • Hepatitis risk increases with daily alcohol consumption, or viral hepatitis • INH-induced hepatitis is almost always reversible • INH given alone to persons with active TB disease can lead to INH-resistant TB 	Age Group	Risk	< 20	0.1–0.2%	20–34	0.3%	35–49	0.5%	50–64	1.0–3.0%	≥ 65	2.0–5.0%
Age Group	Risk														
< 20	0.1–0.2%														
20–34	0.3%														
35–49	0.5%														
50–64	1.0–3.0%														
≥ 65	2.0–5.0%														
Rifampin (RMP)	<ul style="list-style-type: none"> • CNS • Dermatologic • Hypersensitivity • Hepatitis • Gastrointestinal • Hematological • Renal <p>* Many drug interactions – refer to Compendium of Pharmaceuticals and Specialties</p>	<ul style="list-style-type: none"> • Baseline bilirubin, serum creatinine, CBC, platelets, and liver enzymes • Repeat measurements if: <ul style="list-style-type: none"> - Baseline results are abnormal - Patient has symptoms of an adverse reaction 	<ul style="list-style-type: none"> • Colours bodily fluids reddish-orange • May permanently discolour contact lenses • By accelerating estrogen metabolism, RMP may interfere with effectiveness of birth control pills; alternative contraceptive method should be advised • Contraindicated in severe chronic liver disease • RMP given alone to persons with active TB disease can lead to resistance. 												

Management of LTBI when treatment is refused, contraindicated or stopped before completion

Patients who cannot or will not start or complete LTBI treatment should be instructed carefully regarding the symptoms of active TB and instructed to return for medical assessment if those symptoms arise. Routine CXR or follow up is not recommended unless the risk of TB disease is high. In this situation, consider regular follow up for 2 years, as this is the period of highest risk (e.g., at 6, 12 and 24 months). For further information, contact your local health unit.

Source: CTS, 2013

Additional Information: Interferon Gamma Release Assays (IGRAs)

- Two types of IGRAs are approved by Health Canada for use: QuantiFERON-TB Gold In-Tube (QFT) and TSPOT.
- Currently, these tests are not covered by OHIP. At printing, QFT testing is currently available on a limited basis through Gamma-Dynacare Medical Laboratories. Refer to www.gamma-dynacare.com/Content/HealthcareProviders/ImportantNotices.aspx?expandable=1

Websites

www.tstin3d.com www.bcgatlas.org
www.phac-aspc.gc.ca www.cdc.gov/tb/
www.who.org www.on.lung.ca
www.lung.ca

For more information or to order more copies:

Toronto Public Health
416-338-7600
toronto.ca/health

References

1. Greenaway, C., et al. Tuberculosis: Evidence review for newly arriving immigrants and refugees. CMAJ 2011; 183 (12): E852 - E857.
2. Canadian Tuberculosis Standards, 7th edition, Public Health Agency of Canada and the Canadian Lung Association/Canadian Thoracic Society, 2013, p. 125A.
3. Canadian Pharmacists Association. (2013). Compendium of Pharmaceuticals and Specialties (e-CPS). Retrieved Sept. 2013 from <https://www.e-therapeutics.ca/home.faq.action>
4. Canadian Tuberculosis Standards, 7th edition, Public Health Agency of Canada and the Canadian Lung Association/Canadian Thoracic Society, 2013.
5. Centers for Disease Control and Prevention. (2000). 6th edition. Core Curriculum on Tuberculosis. Treatment of Latent Tuberculosis (Chap. 5), updated 2013. Retrieved from <http://www.cdc.gov/TB/education/corecurr/default.htm>

November 2013

THE  LUNG ASSOCIATION™

416.338.7600  PH1311SS246
toronto.ca/health